Product Description
Mechanisms of Action: 5-HT2A Inverse Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Luye Pharma Group Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease|Hallucinations|Parkinson's Disease|Psychotic Disorders|Schizophrenia|Symptoms of Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06793995 |
LY03017/CT-CHN-102 | P1 |
Not yet recruiting |
Schizophrenia|Alzheimer Disease|Psychotic Disorders|Symptoms of Alzheimer Disease|Parkinson's Disease |
2025-10-31 |
2025-01-28 |
Primary Endpoints |
|
NCT06980207 |
LY03017/CT-CHN-103 | P1 |
Not yet recruiting |
Psychotic Disorders|Alzheimer Disease|Symptoms of Alzheimer Disease|Parkinson's Disease|Schizophrenia|Hallucinations |
2025-10-01 |
2025-05-21 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|